<DOC>
	<DOCNO>NCT00796497</DOCNO>
	<brief_summary>Given 5-HT3 receptor indirect inhibitor cortico-mesolimbic DA release , 5-HT3 receptor antagonist ondansetron augmentation might potentially efficacy treatment resistant Obsessive Comulsive Disorder ( OCD ) patient combine SRIs antipsychotic .</brief_summary>
	<brief_title>Ondansetron Treatment Resistant Obsessive Compulsive Disorder ( OCD )</brief_title>
	<detailed_description>METHOD : Fourteen patient DSM-IV diagnosis treatment resistant OCD , stable treatment SSRI 's neuroleptic augmentation enter 12-week single blind trial ondansetron initiate dose 0.25 mg twice daily 6 week , titrate 0.5 mg twice daily 6 week .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>1. adult age 18 55 2. YaleBrown ObsessiveCompulsive Scale ( YBOCS ) score ≥ 20 ≥ 12 week treatment establish effective dose Selective Serotonin Reuptake Inhibitors clomipramine ≥ 10 week augmentation treatment antipsychotic ( risperidone least 2 mg/day quetiapine least 150 mg/day ; olanzapine least 5mg/day ; haloperidol titrate least 10 mg/day ; aripiprazole least 10 mg/day ) 1. history alcohol substance abuse 2. current severe depressive symptom , bipolar disorder , panic disorder , schizophrenia , psychiatric condition 3. heart disease , arrhythmia , liver problem , include cirrhosis , seizure , glaucoma serious medical disease 4. hoard Obsessive Compulsive symptom 5. woman childbearing potential use medically acceptable contraceptive method .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Obsessive Compulsive Disorder</keyword>
	<keyword>5-ht3</keyword>
	<keyword>ondansetron</keyword>
</DOC>